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Gitelman syndrome (GS) is a rare, salt-losing tubulopathy
characterized by hypokalemic metabolic alkalosis with
hypomagnesemia and hypocalciuria. The disease is
recessively inherited, caused by inactivating mutations in
the SLC12A3 gene that encodes the thiazide-sensitive
sodium-chloride cotransporter (NCC). GS is usually detected
during adolescence or adulthood, either fortuitously or in
association with mild or nonspeciﬁc symptoms or both. The
disease is characterized by high phenotypic variability and
a signiﬁcant reduction in the quality of life, and it may be
associated with severe manifestations. GS is usually
managed by a liberal salt intake together with oral
magnesium and potassium supplements. A general
problem in rare diseases is the lack of high quality evidence
to inform diagnosis, prognosis, and management. We
report here on the current state of knowledge related to
the diagnostic evaluation, follow-up, management, and
treatment of GS; identify knowledge gaps; and propose a
research agenda to substantiate a number of issues related
to GS. This expert consensus statement aims to establish
an initial framework to enable clinical auditing and thus
improve quality control of care.
Kidney International (2017) 91, 24–33; http://dx.doi.org/10.1016/
j.kint.2016.09.046
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G itelman syndrome (GS), also referred to as familialhypokalemia-hypomagnesemia, is a salt-losing tubul-opathy characterized by hypokalemic metabolic alka-
losis with hypomagnesemia and hypocalciuria.1,2 With a
prevalence at w1 to 10 per 40,000, and potentially higher
in Asia,3 GS is arguably the most frequent inherited tubulop-
athy.4 The disease is caused by biallelic inactivating mutations
in the SLC12A3 gene encoding the thiazide-sensitive sodium-
chloride cotransporter (NCC) expressed in the apical mem-
brane of cells lining the distal convoluted tubule.5 To date,
>350 mutations scattered throughout SLC12A3 have been
identiﬁed in GS patients.6,7 The majority of patients are com-
pound heterozygous for SLC12A3 mutations, but a signiﬁcant
number of GS patients are found to carry only a single
SLC12A3 mutation.
The presence of both hypocalciuria and hypomagnesemia
is highly predictive for the clinical diagnosis of GS, although
hypocalciuria is highly variable and hypomagnesemia may be
absent.1,8,9 The use of clinical and biological features to
differentiate from other salt-losing nephropathies is difﬁcult
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in some cases. A GS-like phenotype, including hypomagne-
semia and hypocalciuria, has also been associated with
mutations in the CLCNKB gene encoding the chloride
channel ClC-Kb, the cause of classic Bartter syndrome ([cBS]
or Bartter syndrome type III). The localization of ClC-Kb in
the distal convoluted tubule explains the phenotypic overlap
with GS.10,11 Genetic testing is increasingly available for GS,
but it remains expensive.
GS has long been considered a benign tubulopathy, usually
detected during adolescence or adulthood. Indeed, the con-
dition may be asymptomatic or associated with relatively mild
or nonspeciﬁc symptoms or both such as muscular weakness,
fatigue, salt craving, thirst, nocturia, or cramps. However, this
view has been challenged by reports emphasizing the
phenotypic variability and potential severity of the disease.12
Cruz et al.13 showed that GS is associated with a signiﬁcant
reduction in the quality of life—similar to that associated
with congestive heart failure or diabetes. Severe manifesta-
tions, such as early onset (before age 6 years), growth retar-
dation, chondrocalcinosis, tetany, rhabdomyolysis, seizures,
and ventricular arrhythmia have been described.13–15 Of note,
in many reports of severe complications, the diagnosis of GS
was established on clinical rather than genetic grounds,
potentially creating confusion with related disorders including
cBS. Yet, phenotypic variability has also been documented in
genetically conﬁrmed GS patients, including in patients with
identical SLC12A3 mutations.16 A combination of genotype,
sex, modiﬁer genes, compensatory mechanisms, as well as
environmental factors or dietary habits might be involved in
such variability.17
GS is usually managed by a liberal salt (NaCl) intake,
together with oral magnesium and potassium supplements.
Potassium-sparing diuretics, renin angiotensin system
blockers including angiotensin-converting-enzyme inhibitors
and angiotensin receptor blockers, and nonsteroidal anti-
inﬂammatory drugs are sometimes used. However, evidence
supporting the efﬁcacy, tolerability, and safety of these treat-
ment options (either as standalone therapy or in combina-
tions) in GS patients is limited. Information about long-term
outcomes in GS is lacking. In particular, long-term conse-
quences such as chondrocalcinosis, chronic kidney disease,
secondary hypertension, and cardiac arrhythmias, and man-
agement during pregnancy need to be considered.
Despite the insights gained since its genetic elucidation in
1996, much mystery still surrounds GS. Further efforts are
needed to substantiate issues including the following: diag-
nostic criteria and methods; clinical workup and follow-up;
phenotypic heterogeneity; nature and severity of the
biochemical abnormalities and clinical manifestations; and
treatment and long-term consequences of the disease. There-
fore, Kidney Disease: Improving Global Outcome (KDIGO)
hosted a controversies conference to assess the current state of
knowledge related to GS, identify knowledge gaps, and propose
a research agenda. This report summarizes the guidance for
clinical practice and future research developed at this confer-
ence by a global multidisciplinary panel of experts.
Clinical characteristics and diagnosis
GS presents mainly in adolescents and adults but can also be
encountered in children, as early as in the neonatal
period.15,18 The key clinical complaints and manifestations
suggesting a diagnosis of GS (Table 1) include the following:
salt craving (i.e., preference for salty food or a salted treat
during childhood); muscle weakness, fatigue, limited sport
performance or endurance; episodes of fainting, cramps,
tetany, paresthesia, carpopedal spasms; growth retardation,
pubertal delay, short stature; thirst or abnormal drinking
behavior; episodes of abdominal pain. Dizziness, vertigo,
polyuria, nocturia, palpitations, joint pain, and visual prob-
lems may be reported in adults.
The proposed biochemical criteria for suspecting a diag-
nosis of GS (Table 2) include the following: documented
chronic hypokalemia (<3.5 mmol/l) concomitant with inap-
propriate renal potassium wasting (spot urine, potassium-
creatinine ratio >2.0 mmol/mmol [>18 mmol/g]), in
absence of potassium-lowering drugs; metabolic alkalosis; hy-
pomagnesemia (<0.7 mmol/l [<1.70 mg/dl], [Supplementary
Table S1]); inappropriate renal magnesium wasting19 (frac-
tional excretion of magnesium >4%);19,20 hypocalciuria (spot
urine, calcium-creatinine ratio <0.2 mmol/mmol [<0.07
mg/mg] in adults, [Supplementary Table S1]; normal ranges of
calcium-creatinine ratio are different in children,
[Supplementary Table S2]); high renin (activity or plasma
levels); fractional excretion of chloride >0.5%; normal or low
blood pressure; normal renal ultrasound with absence of
nephrocalcinosis or renal abnormalities. If plasma electrolyte
levels are normal or close to normal in a patient taking
potassium or magnesium supplements or both, these sup-
plements should be stopped for at least 48 hours in order to
potentially unmask the abnormalities. Plasma and urine
samples should be obtained concomitantly. No evidence
supports the need for 24-hour urine collection; spot urine
samples are usually sufﬁcient to establish the diagnosis.
Arguments against the diagnosis of GS (Table 2) include
the following: a family history of renal malformations or any
Table 1 | Clinical manifestations encountered in Gitelman
syndrome patients
Most common
(>50% of
patients)
Prominent
(20% to 50%
of patients)
Occasional
(<20%)
Rare
(case reports)
Salt craving
Cramps, muscle
weakness
Fatigue
Dizziness
Nocturia
Thirst, polydipsia
Paresthesia,
numbness
Palpitations
Low blood
pressure
Fainting
Polyuria
Arthralgia
Chondrocalcinosis
Prolonged
QT interval
Febrile episodes
Early onset
(before age 6)
Failure to thrive
Growth retardation
Pubertal delay
Vertigo, ataxia
Carpopedal
spasm, tetany
Vomiting
Constipation
Enuresis
Paralysis
Seizure
Ventricular
tachycardia
Rhabdomyolysis
Blurred vision
Pseudotumor
cerebri
Sclerochoroidal
calciﬁcations
Adapted, with permission, from Devuyst et al.83
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kidney disease dominantly transmitted; the presence of a
renal malformation (e.g., unilateral kidneys, polycystic kid-
neys, etc.); a history of polyhydramnios or hyperechogenic
fetal kidneys; presentation before age 3 years; chronic use of
diuretics or laxatives; lack of hypokalemia or inconsistent
hypokalemia in absence of substitutive therapy; long history
of hypertension; manifestations of increased extracellular
ﬂuid volume. Of note, the presence of arterial hypertension
does not exclude the diagnosis of GS in adults.21,22
Conﬁrmation of clinically suspected GS rests on genetic
testing, which should be offered to all subjects. The diagnosis
of GS is proven by identiﬁcation of biallelic inactivating
SLC12A3 mutations. In view of the rapid progress of genetic
testing, hydrochlorothiazide testing is no longer recom-
mended as a diagnostic tool in GS because of the related risks:
when it is used diagnostically (i.e., to differentiate from
Bartter syndrome), there is a risk of acute volume depletion in
subjects with loop of Henle defect.8 Other limitations include
testing in children or in patients taking medications affecting
tubular transport processes. Hydrochlorothiazide in general
may also induce acute interstitial nephritis and hypersensi-
tivity reactions. Unless speciﬁc manifestations (e.g., signiﬁ-
cant proteinuria) are encountered, a renal biopsy is not
necessary for the diagnosis of GS.
The differential diagnosis of GS includes cBS. The latter is
more likely when the presentation occurs at young age
(<3 years), with failure to thrive, polyuria, and normal
plasma magnesium levels. However, cBS and GS may be
clinically indistinguishable.10,11,23 Mutations in the HNF1B
gene encoding the transcription factor HNF1-b can mimic
the electrolyte abnormalities (particularly hypomagnesemia)
encountered in GS. The presence of maturity onset diabetes
of the young, early chronic kidney disease, family history
compatible with a dominant mode of inheritance, abnormal
liver enzymes, renal or urogenital malformations or kidney
cysts should point to HNF1B-related disorders. HNF1B
mutations can occur in the heterozygous state, either
inherited or de novo, and comprise point mutations as well as
whole gene deletions.24 Approximately 50% of patients
develop hypomagnesemia due to renal magnesium wasting,
often accompanied by hypocalciuria, indicating that the distal
convoluted tubule is involved.25 Mutations in the KCNJ10
gene coding for the inwardly rectifying potassium channel
KCNJ10/Kir4.1 cause an autosomal recessive disorder char-
acterized by epilepsy, ataxia, sensorineural deafness, and
tubulopathy (or EAST syndrome). The extrarenal features of
EAST syndrome allow it to be distinguished from GS.26
The differential diagnosis of GS also includes diuretic and/
or laxative abuse, which is unusual in children, and chronic
vomiting. Measurement of urinary chloride (e.g., < 25 mEq/l
for surreptitious vomiting) and a urine screen for diuretics
(e.g., by mass spectrometry) can help exclude GS in these
patients.27 The association of hypokalemic metabolic alkalosis
with hyperreninemic secondary aldosteronism is also found
in other familial disorders affecting the kidneys or the
gastrointestinal tract, or it can be acquired. For example,
patients with cystic ﬁbrosis are prone to develop episodes of
hyponatremic, hypochloremic dehydration with metabolic
alkalosis.28 GS-like manifestations have been reported as a
rare complication of the use of cisplatin.29 Autoimmune
disorders may cause renal tubular disorders, potentially due to
autoantibodies against tubular components.30 Typical features
of GS have been associated with autoimmune disorders
including iritis and arthritis31 and Sjögren syndrome.32
Because of its rarity, GS may not be suspected as a distinct
entity. As the clinical manifestations may be nonspeciﬁc, the
disease is often discovered fortuitously during biochemical
workup. The value of checking plasma potassium and mag-
nesium levels in the workup of indirectly related conditions
such as epilepsy, growth retardation, pubertal delay, and
neuromuscular disorders should be stressed.
Clinical manifestations and workup
Most of the clinical problems in GS are linked to electrolyte
disturbances, in particular chronic salt loss, hypokalemia, or
Table 2 | Diagnostic criteria for Gitelman syndrome
Criteria for suspecting a diagnosis of GS
 Chronic hypokalemia (<3.5 mmol/l) with inappropriate renal
potassium wasting (spot potassium-creatinine ratio >2.0 mmol/
mmol [>18 mmol/g])
 Metabolic alkalosis
 Hypomagnesemia (<0.7 mmol/l [<1.70 mg/dl]) with inappropriate
renal magnesium wasting (fractional excretion of magnesium >4%)
 Hypocalciuria (spot calcium-creatinine ratio <0.2 mmol/mmol [<0.07
mg/mg]) in adults.a
 High plasma renin activity or levels
 Fractional excretion of chloride > 0.5%b
 Low or normal-low blood pressure
 Normal renal ultrasound
Features against a diagnosis of GS
 Use of thiazide diuretics or laxatives
 Family history of kidney disease transmitted in an autosomal
dominant mode
 Absence of hypokalemia (unless renal failure); inconsistent
hypokalemia in absence of substitutive therapy
 Absence of metabolic alkalosis (unless coexisting bicarbonate loss or
acid gain)
 Low renin values
 Urine: low urinary potassium excretion (spot potassium-creatinine
ratio <2.0 mmol/mmol [<18 mmol/g]); hypercalciuria
 Hypertension,c manifestations of increased extracellular ﬂuid volume
 Renal ultrasound: nephrocalcinosis, nephrolithiasis, unilateral
kidneys, cystic kidneys
 Prenatal history of polyhydramnios, hyperechogenic kidneys
 Presentation before age 3 yearsc
Criteria for establishing a diagnosis of GS
 Identiﬁcation of biallelic inactivating mutations in SLC12A3
GS, Gitelman syndrome.
Listed are typical features arguing for or against a diagnosis of GS based on pub-
lished evidence and collective clinical experience. Features in an individual patient
may vary and ultimately the diagnosis rests on genetic testing. Thus, age of onset
before 3 years of age has been reported, as has hypertension (in middle-aged and
elderly patients with GS) and renal cysts.84
aNormal calciuria ranges are different in children due to lower creatinine excretion
(see Supplementary Table S2).
bThe value of fractional excretion of chloride is based on expert opinion (high
variability of urinary chloride alone) and requires veriﬁcation from published clinical
observations.
cHypertension and presentation before age 3 years do not exclude GS (see text).
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hypomagnesemia, or a combination of these. Increasing
awareness of the disease is reﬂected by an increased
number of patients identiﬁed, favoring the report of rare
complications (Table 1) that should warrant the appropriate
workup.
Because GS originates from the distal convoluted tubule,
the salt and water losses in GS patients are less pronounced
than in antenatal BS or cBS because urinary concentrating
ability is largely intact. GS patients are often asymptomatic or
present with symptoms such as muscle weakness, fatigue, salt
craving, thirst, nocturia, constipation, cramps, carpopedal
spasms, or tetanic episodes triggered by hypomagnese-
mia.33,34 Blood pressure is typically low, particularly for
patients with severe hypokalemia and hypomagnesemia.35
Complications of GS include chondrocalcinosis36 and scle-
rochoroidal calciﬁcations.37 This is because magnesium ions
increase the solubility of calcium pyrophosphate crystals and
are important activators for tissue-nonspeciﬁc alkaline
phosphatase, which hydrolyzes pyrophosphates (PPi) into
inorganic phosphate (Pi), hence hypomagnesemia may pro-
mote the formation of calcium pyrophosphate crystals in
joints and sclera.38 In addition, increased renal calcium
reabsorption may contribute to calcium deposition, and pa-
tients with GS have higher bone mineral density, similar to
chronic thiazide treatment, associated with a decreased rate of
bone remodeling.39,40 They may also present with growth
retardation, pubertal delay, and short stature, reﬂecting an
alteration in the growth hormone/insulin-like growth factor I
axis or pleiotropic effects resulting from the biochemical
disturbance.41 Hypokalemic rhabdomyolysis has been re-
ported in several GS patients.42
Ultrasound or X-ray examination should be performed in
case of speciﬁc complaints that are suggestive of chon-
drocalcinosis. Ophthalmology examination is indicated when
sclerochoroidal calciﬁcations are suspected.37
Potassium and magnesium depletion prolong the duration
of the action potential in cardiomyocytes, resulting in pro-
longed QT interval in w50% of the patients, which could
lead to an increased risk for ventricular arrhythmias.43,44 GS
patients who presented with long runs of ventricular tachy-
cardia have been reported.14 Given isolated reports on cardiac
arrhythmias, long QT and sudden death in GS, an electro-
cardiogram (ECG) should be performed at rest to assess
rhythm and QT duration. A further cardiology workup
(e.g., Holter, stress ECG) is indicated where patients complain
of palpitations or syncope, or if the ECG abnormalities persist
despite attempted improvement of the biochemical
abnormalities.45
Patients with GS may present glucose intolerance or in-
sulin resistance or both secondary to chronic hypomagnese-
mia and hypokalemia.46 Nevertheless, increased insulin
sensitivity and protection from atherogenesis due to blunted
angiotensin II signaling and reduced oxidative stress have also
been reported.47,48
Reports suggest that GS may be associated with glomerular
proteinuria due to abnormalities of the glomerular basement
membrane.22,49 Chronic kidney disease might develop in GS
patients due to either chronic hypokalemia, which is associ-
ated with tubulointerstitial nephritis, tubule vacuolization,
and cystic changes, or volume depletion and increased renin-
angiotensin-aldosterone, which may contribute to renal
damage and ﬁbrosis.21,50,51
Many patients with GS present with abdominal pain,
which may be due to intestinal paresis because of hypokale-
mia or intolerability of potassium and magnesium supple-
mentation. These complaints should be investigated
appropriately and treated accordingly. Impaired renal phos-
phate handling52 has also been reported.
Genetic testing
The detection of biallelic inactivating SLC12A3 mutations is
crucial for the diagnosis of GS. The analytical sensitivity
(i.e., the proportion of positive tests if 2 mutations in the
SLC12A3 exons or exon-intron boundaries are present) and
speciﬁcity (i.e., proportion of negative tests if 2 mutations in
SLC12A3 are not present) of genetic testing for GS is 90% to
100% and 100%, respectively. Because there are GS patients
who do not have 2 mutations in SLC12A3 (i.e., a mutation in
the noncoding regions or in another gene, which are not
included in the test), the clinical sensitivity (proportion of
positive tests if the disease is present) is 65% to 80%,
depending on the genetic methods used.7,12,50,53–55 Pathogenic
SLC12A3mutations include larger rearrangements (deletions),
which can be picked up by multiplex ligation-dependent probe
ampliﬁcation,7 and intronic mutations, which can be screened
for by cDNA analysis of lymphocytes.50,56 As genetic testing
becomes more accessible and comprehensive, it should be
offered to all patients with a clinical suspicion of GS (minimal
criteria). It should be performed in a laboratory accredited for
diagnostic genetic testing.
The use of a next generation sequencing–based gene panel
to parallel sequence (in 1 test) all genes that are relevant in the
differential diagnosis of GS is recommended. Different next
generation sequencing gene panels are available; it should at
least include the SLC12A3, CLCNKB, and HNF1B genes. If
only a single variant has been identiﬁed by next generation
sequencing panel sequencing, the analysis should be com-
plemented with a test for a deletion (multiplex ligation-
dependent probe ampliﬁcation) on the other allele. If Sanger
sequencing is the only available technique in the diagnostic lab,
sequential testing of SLC12A3, CLCNKB, and HNF1B should
be performed, and if necessary complemented by multiplex
ligation-dependent probe ampliﬁcation testing for these genes.
It must be kept in mind that in 15% to 20% of patients,7,57
even after multiplex ligation-dependent probe ampliﬁcation
analysis, only 1 pathogenic mutation is discovered.7 In these
cases, mutations in regulatory regions including introns of
SLC12A3 or in another gene might be the underlying second
molecular defect. At present, these mutations are only searched
for in speciﬁc cases (e.g., severe cases, Asianbackground, genetic
counseling purposes), but this may change with dissemination
of next generation sequencing techniques in diagnostic labs.
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Genetic counseling should be offered to any patient with
GS and to parents with a young child suffering from the
disease. This counseling could discuss testing of parents,
siblings and partner. Prenatal diagnosis and preimplantation
genetic diagnosis are technically feasible when 2 pathogenic
SLC12A3 mutations have been identiﬁed. In our experience,
these tests have not been asked for because of the good
prognosis in the majority of GS patients. In very severe cases,
the possible use of these predictive tests could be potentially
discussed.
In the near future, whole exome sequencing and whole
genome sequencing, followed by targeted analysis, will
become the genetic tests of preference in many patients with a
presumed genetic disorder. Careful genetic counseling and
speciﬁc informed consent should always precede those genetic
screening tests.58 It is important to note that with the
increasing availability of new-population–based genetic data
and functional studies, the classiﬁcation of variants may
change: the pathogenicity of previously disease-associated
genetic variants could be questioned and, vice versa, vari-
ants of previously unknown signiﬁcance could be conﬁrmed
as pathogenic.59 Diagnostic laboratories should take into ac-
count the evolving population and consider in vitro studies to
interpret patient results appropriately.60
Treatment
Because GS is caused by a primary defect in a sodium-
chloride cotransporter, ad libitum NaCl intake should be
strongly advocated. We recommend to encourage patients to
follow their propensity for salt consumption. As yet, the
potential beneﬁt of pharmacological NaCl supplements added
to liberal salt intake has not been tested.
Individualized lifelong oral potassium or magnesium
supplementation or both is the mainstay of treatment for
patients with GS. In the presence of hypomagnesemia, mag-
nesium supplementation should be considered ﬁrst, because
magnesium repletion will facilitate potassium repletion and
reduce the risk of tetany and other complications.19,33
Many symptoms are improved by potassium or magne-
sium supplementation or both, but there is no evidence
correlating the severity of blood levels with the intensity of
symptoms. A reasonable target for potassium may be
3.0 mmol/l and magnesium 0.6 mmol/l (1.46 mg/dl).
Achieving these targets can be difﬁcult in some patients and
supplementation with large doses may result in serious side
effects including gastric ulcers, vomiting, or diarrhea with
worsening biochemistries. An individual balance between
improvement in blood values and side effects should be
established. Realistic target values may be lower for some
patients and may also change with time. Adherence to the
supplementation may be inﬂuenced by cost—because variable
reimbursement policies exist in different countries.
Potassium supplements should be given as chloride (KCl)
because chloride is the main anion lost in the urine and
patients are alkalotic. A starting dose of $40 mmol KCl
(1–2 mmol/kg in children), in divided doses throughout the
day, is suggested. Potassium supplements should not be taken
on an empty stomach to minimize gastrointestinal irritation
or damage. KCl supplements can be administered in water, as
syrup, or in a slow-release formulation according to each
patient’s preference. The dose will be titrated individually
(side effects vs. symptoms), knowing that the maintenance
dose may be high. Potassium-rich foods should be recom-
mended, with the caution that some of them contain high
carbohydrates and calories (Supplementary Table S3).
Intravenous KCl may be necessary either when the patient
cannot take oral drugs or when the potassium deﬁcit is very
severe, causing cardiac arrhythmias, quadriplegia, respiratory
failure, or rhabdomyolysis.61 KCl should be diluted in saline,
usually to a concentration of 40 mmol/l. In general, no more
than 50 mmol/l should be given through a peripheral vein at a
maximum rate of 10 mmol/h, because higher concentrations
of potassium are very irritating, resulting in pain and sclerosis
of the vein. For central venous lines, the maximum concen-
tration is usually 80 mmol/l with a maximum rate of
20 mmol/h (depending on hypokalemia, ECG monitoring).
Beyond 10 mmol/h, the patient should be monitored in a
high-dependency environment or area. Severe hyperkalemia
may develop when acute renal failure develops in a patient
taking exogenous potassium supplementation.62
Oral administration of magnesium supplements is the
preferred way to correct magnesium deﬁciency, which ag-
gravates hypokalemia and renders it refractory to treatment
by potassium.63 All types of magnesium salts are effective, but
their bioavailability is highly variable (Supplementary
Table S4), resulting in osmotic diarrhea at high doses.64
Organic salts (e.g., aspartate, citrate, lactate) have a higher
bioavailability than magnesium oxide and hydroxide.64 MgCl2
will also compensate the urinary loss of chloride. The rec-
ommended starting dose is 300 mg/day (12.24 mmol) of
elemental magnesium (5 mg/kg in children, i.e., 0.2 mmol/kg),
in slow-release tablets when possible. The supplementation
should be divided into 2 to 4 doses, preferably with meals.
Dosage titration based onblood levels and intestinal tolerance is
usually necessary. Persistent diarrhea may mandate a drop in
dosage, which paradoxically may improve serum levels thanks
to increased bioavailability or decreased intestinal transit time
or both.65 A list of magnesium-rich foods is provided in
Supplementary Table S5.
Intravenous infusion of magnesium should be reserved
either for patients presenting with acute, severe complications
of hypomagnesemia (e.g., tetany, cardiac arrhythmias), or in
cases of digestive intolerance to oral supplements. In cases of
acute tetany, 20% MgCl2 should be administered intrave-
nously (0.1 mmol Mg/kg per dose) and can be repeated every
6 hours.4
In cases of persistent, symptomatic hypokalemia when
supplements are not sufﬁcient despite adherence or when side
effects are unacceptable or both, the use of potassium-sparing
diuretics,66,67 renin angiotensin system blockers,68 or
nonsteroidal anti-inﬂammatory drugs, such as indomethacin,
or a combination of these have been proposed.69–71 The
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potassium-sparing diuretics amiloride, spironolactone, po-
tassium canrenoate, and eplerenone can be useful, both to
increase serum potassium levels in patients resistant to sup-
plements and to treat magnesium depletion that is worsened
by elevated aldosterone levels.66 The use of spironolactone is
complicated by its antiandrogenic effects such as gyneco-
mastia, hirsutism, erectile dysfunction, and menstrual irreg-
ularities, which are particularly difﬁcult in adolescents and
young adults. Eplerenone is a selective aldosterone antagonist,
with signiﬁcantly lower afﬁnity for androgen, progesterone,
and glucocorticoid receptors in comparison with spi-
ronolactone and has therefore no antiandrogenic side
effects.72 These drugs compound the renal salt wasting and
should thus be started cautiously to avoid hypotension.
Concomitant salt supplementation should be considered.
The use of renin angiotensin system inhibitors (angio-
tensin-converting-enzyme inhibitors and angiotensin recep-
tor blockers) has been occasionally reported in the treatment
of GS.68 These drugs also aggravate renal sodium wasting and
increase the risk of symptomatic hypovolemia; they should be
stopped in case of acute, salt-losing complications, such as
vomiting or diarrhea. Prostaglandin synthase inhibitors such
as indomethacin are rarely used in GS, because urinary
prostaglandin E2 levels in GS are usually normal. Refractory
hypokalemia has also been treated with the speciﬁc COX-2
inhibitor rofecoxib,71 but the use of this drug is limited by
its long-term cardiovascular effects.
Recently, an open-label, randomized, crossover study was
conducted to compare the efﬁcacy and safety of 6-week
treatment with once-daily doses of 75 mg slow-release indo-
methacin, 150 mg eplerenone, or 20 mg amiloride added to
constant potassium and magnesium supplementation in 30
GS patients.73 Each drug increased plasma potassium con-
centration by about 0.3 mmol/l. Amiloride and eplerenone
aggravated sodium depletion, whereas indomethacin was
associated with decreased estimated glomerular ﬁltration rate
and caused gastrointestinal intolerance in one-third of sub-
jects. Despite a documented effect on hypokalemia, indo-
methacin and other nonsteroidal anti-inﬂammatory drugs
should be used with caution due to their short- and long-
term gastrointestinal side effects and nephrotoxicity.
A series of drugs should be avoided or used with caution in
patients with GS (Table 3). These include drugs slowing sinus
rhythm or inﬂuencing the QT interval (e.g., negative chro-
notropic drugs), drugs potentially exacerbating hypomagne-
semia (e.g., proton-pump inhibitors, gentamicin, antiviral
drugs), and acetazolamide.
The cornerstone of the prevention of chondrocalcinosis is
magnesium supplementation. Both oral nonsteroidal anti-
inﬂammatory drugs and low-dose oral colchicine are effec-
tive systemic treatments for acute chondrocalcinosis.74,75
Nonsteroidal anti-inﬂammatory drugs have to be used
with caution in GS due to risk of kidney injury, whereas
colchicine treatment can increase the laxative effect of oral
magnesium supplementation. Intra-articular corticosteroids
may be considered in patients in whom other drugs are
contraindicated or not tolerated. Intermittent general corti-
costeroids, as well as methotrexate, have been proposed for
patients with severe chondrocalcinosis.76
Management and follow-up
The management of GS should be individualized, with
appropriate change with time and demands. At least annual
follow-up in a nephrology clinic to monitor potential com-
plications and evolution is advocated. The symptoms may
increase with aging, irrespective of the control of hypokale-
mia. The latter may be easier after menopause. Patients
should be educated about side effects of the supplements, in
particular abdominal pain and diarrhea induced by magne-
sium salts and gastric irritation from potassium chloride.
Physicians also should be attentive to other factors that could
hamper adherence to the supplements, including socioeco-
nomic difﬁculties, lack of reimbursement, adolescence, tran-
sition period, work conditions, etc. The transition phase
between pediatric and adult care is particularly important.
Long-term studies are needed to assess the natural history
of GS and the individual risks of chronic hypokalemia and
hypomagnesemia in terms of metabolic syndrome, cardiac
arrhythmias, chronic kidney disease, blood pressure control,
Table 3 | Drugs associated with hypokalemia and
hypomagnesemia
Site of loss Drugs
Hypokalemia
Shift from extracellular
ﬂuid to intracellular
ﬂuid compartment
b2-receptor agonists
Insulin (high dose) with glucose
Xanthines (theophylline, caffeine)
Verapamil (in overdose)
Sodium bicarbonate
Extrarenal Laxatives
Renal
Antimicrobials Nafcillin, ampicillin, penicillin, aminoglycosides,
amphotericin B, foscarnet
Diuretics Acetazolamide
Furosemide and other loop diuretics
Thiazides
Mannitol
Mineralocorticoids Fludrocortisone
Antiepileptic Topiramate
Hypomagnesemia
Extrarenal Proton pump inhibitor
Renal
Antimicrobials Drug-induced renal Fanconi syndrome:
Aminoglycosides (gentamycin, streptomycin,
tobramycin), pentamidine, amphotericin B,
foscarnet, antiretroviral therapy
Diuretics Furosemide
Thiazide
Antitumoral Cisplatin
Tyrosine kinase inhibitors
Immunosuppressants Calcineurin inhibitors (cyclosporine, tacrolimus)
Mycophenolate
Anti-EGF receptors (cetuximab, panitumumab)
EGF, epidermal growth factor.
See also Sung et al.85,86
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and propensity to develop chondrocalcinosis. To date, there is
no evidence that GS affects life expectancy.
The known aggravation of hypokalemia and hypomagne-
semia during pregnancy requires the early institution of a
joint management plan involving nephrology and specialized
obstetrics, as well as appropriate adaptations in the supple-
mentation.77–79 The outcome of mother and fetus of GS
pregnancies described to date is favorable, with no cases of
arrhythmia or other serious cardiac complication reported for
either the mother or fetus.77,78 Importantly, angiotensin re-
ceptor blockers and angiotensin-converting-enzyme in-
hibitors should be stopped during pregnancy because of
signiﬁcant fetal risks.80,81 Monitoring of plasma electrolyte
levels is advised during labor. After delivery, the treatment of
the mother may return to baseline supplementation and
follow-up.
Caution should be taken when patients with GS
undergo anesthesia. Hypokalemia and hypomagnesemia can
potentiate the effects of local and general anesthetic agents
(e.g., neuromuscular blockade during general anesthesia and
adrenalin use in regional blockade). There is no deﬁnitive
evidence to suggest exact preoperative levels of potassium and
magnesium that are safe. In the general population, the UK
National Institute for Health and Care Excellence (NICE)-
approved guidelines suggest aiming for potassium levels
of $3.0 mmol/l and magnesium 0.5 mmol/l (1.22 mg/dl).82
The electrolyte disturbances in children with GS are
associated with pubertal and growth delay.12 If growth failure
is evident despite adequate supplementation, formal assess-
ment of pubertal status and growth hormone levels is rec-
ommended. Treatment with growth hormone is likely to
beneﬁt those with true growth hormone deﬁciency if pro-
vided with optimized biochemical control.
Education about the cause and nature of the disease is
critical for patient empowerment. This information can be
provided through a variety of media, including personal ed-
ucation in a clinical setting; information leaﬂets; web-based
information and patient-led forums (Supplementary
Table S6); patient and family groups’ support events.
Patients, their caregivers or both need to know what to do
in case of an emergency. A medical identity bracelet
(e.g., Medic-Alert, http://www.medicalert.org.uk/) may be
useful. If traveling, patients should carry a doctor’s letter with
them that lists medications required, and they must not be
prevented from carrying adequate supplements for their
journey in hand luggage. ‘Sick day rules’ are helpful in case of
intercurrent illness (Supplementary Table S7). It is important
to reexplain the disease at different stages of life to the young
adult. Physicians at transition clinics should build up aware-
ness and consciousness of the patient’s disease and treatment
and the implications thereof for daily life. Patients and their
families should be encouraged to contact local or regional
patient organizations (Supplementary Table S6).
GS can compromise school performance (e.g., absence,
difﬁculty in concentration). Country-speciﬁc measures exist
to compensate schooling limitations of these children. They
should be used or developed according to the local practice,
on an individual basis.
GS can also compromise work performance. In larger
companies, local occupational health physicians may aid pa-
tients in ﬁnding solutions for their speciﬁc health situations.
For example, if fatigue makes working an 8-hour day
impossible, accommodations might include extra rest pe-
riods, reduced hours, or the ability to work at home. Work
shifts may be particularly difﬁcult for GS patients. Patients
may be afraid to disclose their condition because they fear
losing their job. However, patients should be encouraged to
share information about their disease, but not without
providing the employer with educational resources about GS.
There is no evidence suggesting that participation in sports
is deleterious in GS. Caution is recommended in cases of
endurance or strenuous exercise or competition practice.
Table 4 | Knowledge gaps and research questions for
Gitelman syndrome
Diagnostic and biomarkers
 Urinary exosomes, including assessment of NCC and pNCC
 Urine values or creatinine ratios establishing wasting for potassium,
sodium, chloride (spot)
 Value of ionized versus total magnesium measurement
Clinical aspects
 Blood pressure control, hypertension (incidence, cause, etc.)
 Cardiovascular complications: conduction, myocardium, predictive
effort ECG, reproducibility, age effect, QT interval, and electrolyte levels
 Metabolic complications: glucose tolerance, role of magnesium
balance
Patient-related outcomes
 Quality of life, disability, sociology, perception of symptoms
 Disability scores
 Self-management techniques
Genetic aspects
 Genetic heterogeneity, causal genes, or modiﬁer genes
 Assessment of the pathogenicity of variants
 Prevalence of SLC12A3 mutations in exome database
 Effect of the carrier state, geographic variations
 Genotype-phenotype correlations, including effect of triple SLC12A3
mutations
 Sex effect
 Establishing prevalence of the disease and the carrier state
Intervention
 Effect of high NaCl supplementation
 Effect of sport, increased muscular mass, potassium supplementation
after exercise
 Deﬁne optimal target values for potassium and magnesium
Outcome and natural history
 Registry, biobanking
 Growth, activity, sports
 Glucose intolerance and metabolic proﬁle
 Renal function, concentration defect, proteinuria, chronic kidney
disease, cysts
 Cardiovascular complications
 Rare complications: pseudotumor cerebri, pectus excavatum, link
with autoimmunity
Mother and child
 Pregnancy and fetal development
Monitoring
 Improve monitoring: noninvasive, frequency, possible trans-
cutaneous measurements
ECG, electrocardiogram; NCC, thiazide-sensitive sodium-chloride cotransporter;
pNCC, phosphorylated thiazide-sensitive sodium-chloride cotransporter.
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Volume depletion in particular should be prevented, and
additional salt or electrolytes or both may help. In cases of
history of cardiac manifestations or prolonged QT, a cardi-
ology workup is advised.
Conclusion and perspectives
GS was ﬁrst described in 1966, and its genetic basis was
elucidated 30 years later. Despite a solid understanding of the
underlying renal mechanism, the wide spectrum of clinical
severity, ranging from incidental diagnosis in essentially
asymptomatic patients to severe disability in others despite
similar biochemical abnormalities, remains an enigma. A
better understanding of the factors involved in this variability
is critical to provide better treatments. Given the high
numbers of incidental diagnoses, it is tempting to speculate
that there may be signiﬁcant underdiagnosis of GS. A list of
identiﬁed knowledge gaps and proposals for a research agenda
are provided in Table 4. As with essentially all rare diseases,
support for evidence-based treatment in GS is limited at best.
Most of the guidance provided in this conference output is
based on clinical experience, observational studies or case
reports and is therefore derived from low-grade evidence. We
are fully aware that the guidance provided here will be revised
with time. However, these recommendations represent our
current state of knowledge and constitute an initial frame-
work to enable clinical auditing and thus quality control for
which future treatments can be compared and measured
against.
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